Zobrazeno 1 - 10 of 202 pro vyhledávání: '"Barkay H"'
1
Akademický článek
Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
Autor: Hauser RA; From the University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL., Barkay H; Teva Pharmaceutical Industries Ltd, Netanya, Israel., Fernandez HH; Cleveland Clinic, Center for Neurological Restoration, Cleveland, OH., Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, NY., Factor SA; Jean and Paul Amos Parkinson's Disease and Movement Disorder Program, Emory University, Atlanta, GA., Gross N; Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA., Marinelli L; Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA., Gordon MF; Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA., Barash S; Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA., Finkbeiner S; Teva Branded Pharmaceutical Products R&D, Inc., Parsippany, NJ., Chaijale N; Teva Branded Pharmaceutical Products R&D, Inc, West Chester, PA., Anderson KE; Georgetown University, Department of Psychiatry and Department of Neurology, Washington, DC.
Publikováno v: Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2024 Jul-Aug 01; Vol. 44 (4), pp. 386-396. Date of Electronic Publication: 2024 Jun 21.
Zobrazit plný text záznamu
2
Correction: Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Autor: Frank S; Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Ave., Kirstein 228, Boston, MA, 02215, USA. sfrank2@bidmc.harvard.edu., Anderson KE; Georgetown University, Washington, DC, USA., Fernandez HH; Cleveland Clinic, Cleveland, OH, USA., Hauser RA; University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL, USA., Claassen DO; Vanderbilt University Medical Center, Nashville, TN, USA., Stamler D; Teva Branded Pharmaceutical Products R&D, Inc., La Jolla, CA, USA., Factor SA; Emory University, Atlanta, GA, USA., Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Barkay H; Teva Pharmaceutical Industries Ltd., Netanya, Israel., Wilhelm A; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Alexander JK; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Chaijale N; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Barash S; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Savola JM; Teva Pharmaceuticals International GmbH, Basel, Switzerland., Gordon MF; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Chen M; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Publikováno v: Neurology and therapy [Neurol Ther] 2024 Dec; Vol. 13 (6), pp. 1747-1749.
Zobrazit plný text záznamu
3
Akademický článek
Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
Autor: Frank S; Beth Israel Deaconess Medical Center/Harvard Medical School, 330 Brookline Ave., Kirstein 228, Boston, MA, 02215, USA. sfrank2@bidmc.harvard.edu., Anderson KE; Georgetown University, Washington, DC, USA., Fernandez HH; Cleveland Clinic, Cleveland, OH, USA., Hauser RA; University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL, USA., Claassen DO; Vanderbilt University Medical Center, Nashville, TN, USA., Stamler D; Teva Branded Pharmaceutical Products R&D, Inc., La Jolla, CA, USA., Factor SA; Emory University, Atlanta, GA, USA., Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, NY, USA., Barkay H; Teva Pharmaceutical Industries Ltd., Netanya, Israel., Wilhelm A; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Alexander JK; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Chaijale N; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Barash S; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Savola JM; Teva Pharmaceuticals International GmbH, Basel, Switzerland., Gordon MF; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA., Chen M; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, USA.
Publikováno v: Neurology and therapy [Neurol Ther] 2024 Jun; Vol. 13 (3), pp. 655-675. Date of Electronic Publication: 2024 Apr 01.
Zobrazit plný text záznamu
4
Akademický článek
Safety and Efficacy of Long-Term Deutetrabenazine Use in Children and Adolescents with Tics Associated with Tourette Syndrome: An Open-Label Extension Study.
Autor: Jankovic J; Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology Baylor College of Medicine Houston Texas USA., Coffey B; Department of Psychiatry and Behavioral Sciences, Child and Adolescent Psychiatry University of Miami Miller School of Medicine Miami Florida USA., Claassen DO; Department of Neurology, Division of Behavioral and Cognitive Neurology Vanderbilt University Medical Center Nashville Tennessee USA., Jimenez-Shahed J; Movement Disorders Neuromodulation & Brain Circuit Therapeutics, Departments of Neurology and Neurosurgery Icahn School of Medicine at Mount Sinai New York New York USA., Gertz BJ; Nuvelution TS Pharma Inc. San Francisco California USA., Garofalo EA; Nuvelution TS Pharma Inc. San Francisco California USA., Stamler DA; Teva Branded Pharmaceutical Products R&D, Inc. La Jolla California USA., Wieman M; Teva Branded Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA., Savola JM; Teva Pharmaceuticals International GmbH Basel Switzerland., Harary E; Innovative Medicines, Global Clinical Development Teva Pharmaceutical Industries Ltd. Netanya Israel., Alexander J; Global Medical Affairs Teva Branded Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA., Barkay H; Innovative Medicines, Global Clinical Development Teva Pharmaceutical Industries Ltd. Netanya Israel., Gordon MF; Innovative Medicines, Global Clinical Development Teva Branded Pharmaceutical Products R&D, Inc. West Chester Pennsylvania USA.
Publikováno v: Movement disorders clinical practice [Mov Disord Clin Pract] 2023 Aug 24; Vol. 10 (9), pp. 1388-1398. Date of Electronic Publication: 2023 Aug 24 (Print Publication: 2023).
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Akademický článek
Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
Autor: Hauser RA; University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL, USA. Electronic address: rhauser@usf.edu., Barkay H; Teva Pharmaceuticals, Netanya, Israel., Wilhelm A; Teva Pharmaceuticals, West Chester, PA, USA., Wieman M; Teva Pharmaceuticals, West Chester, PA, USA., Savola JM; Teva Pharmaceuticals International, Basel, Switzerland., Gordon MF; Teva Pharmaceuticals, West Chester, PA, USA.
Publikováno v: Parkinsonism & related disorders [Parkinsonism Relat Disord] 2022 Apr; Vol. 97, pp. 47-51. Date of Electronic Publication: 2022 Mar 02.
Zobrazit plný text záznamu
7
Akademický článek
Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia.
Autor: Sajatovic M; University Hospitals Cleveland Medical Center (MS), Case Western Reserve University School of Medicine, Cleveland, OH. Electronic address: martha.sajatovic@uhhospitals.org., Finkbeiner S; Teva Pharmaceuticals (SF, AW, NCNG, MFG), West Chester, PA., Wilhelm A; Teva Pharmaceuticals (SF, AW, NCNG, MFG), West Chester, PA., Barkay H; Teva Pharmaceuticals (HB), Netanya, Israel., Chaijale N; Teva Pharmaceuticals (SF, AW, NCNG, MFG), West Chester, PA., Gross N; Teva Pharmaceuticals (SF, AW, NCNG, MFG), West Chester, PA., Gordon MF; Teva Pharmaceuticals (SF, AW, NCNG, MFG), West Chester, PA.
Publikováno v: The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry [Am J Geriatr Psychiatry] 2022 Mar; Vol. 30 (3), pp. 360-371. Date of Electronic Publication: 2021 Aug 16.
Zobrazit plný text záznamu
8
Akademický článek
Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
Autor: Hauser RA; University of South Florida Parkinson's Disease and Movement Disorders Center, Tampa, FL, United States., Barkay H; Teva Pharmaceuticals, Netanya, Israel., Fernandez HH; Cleveland Clinic, Cleveland, OH, United States., Factor SA; Emory University, Atlanta, GA, United States., Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, NY, United States., Gross N; Teva Pharmaceuticals, West Chester, PA, United States., Marinelli L; Teva Pharmaceuticals, West Chester, PA, United States., Wilhelm A; Teva Pharmaceuticals, West Chester, PA, United States., Alexander J; Teva Pharmaceuticals, West Chester, PA, United States., Gordon MF; Teva Pharmaceuticals, West Chester, PA, United States., Savola JM; Teva Pharmaceuticals, Basel, Switzerland., Anderson KE; Georgetown University, Washington, DC, United States.
Publikováno v: Frontiers in neurology [Front Neurol] 2022 Feb 23; Vol. 13, pp. 773999. Date of Electronic Publication: 2022 Feb 23 (Print Publication: 2022).
Zobrazit plný text záznamu
9
Akademický článek
Safety and Efficacy of Flexible-Dose Deutetrabenazine in Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial.
Autor: Jankovic J; Baylor College of Medicine, Houston, Texas., Coffey B; University of Miami Miller School of Medicine, Miami, Florida., Claassen DO; Vanderbilt University Medical Center, Nashville, Tennessee., Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, New York., Gertz BJ; Nuvelution TS Pharma Inc., San Francisco, California., Garofalo EA; Nuvelution TS Pharma Inc., San Francisco, California., Stamler DA; Teva Pharmaceuticals, La Jolla, California., Wieman M; Teva Pharmaceuticals, West Chester, Pennsylvania., Savola JM; Teva Pharmaceuticals, Basel, Switzerland., Gordon MF; Teva Pharmaceuticals, West Chester, Pennsylvania., Alexander J; Teva Pharmaceuticals, West Chester, Pennsylvania., Barkay H; Teva Pharmaceuticals, Netanya, Israel., Harary E; Teva Pharmaceuticals, Netanya, Israel.
Publikováno v: JAMA network open [JAMA Netw Open] 2021 Oct 01; Vol. 4 (10), pp. e2128204. Date of Electronic Publication: 2021 Oct 01.
Zobrazit plný text záznamu
10
Akademický článek
Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics Associated With Tourette Syndrome: A Randomized Clinical Trial.
Autor: Coffey B; University of Miami Miller School of Medicine, Miami, Florida., Jankovic J; Baylor College of Medicine, Houston, Texas., Claassen DO; Vanderbilt University Medical Center, Nashville, Tennessee., Jimenez-Shahed J; Icahn School of Medicine at Mount Sinai, New York, New York., Gertz BJ; Nuvelution TS Pharma Inc, San Francisco, California., Garofalo EA; Nuvelution TS Pharma Inc, San Francisco, California., Stamler DA; Teva Pharmaceuticals, La Jolla, California., Wieman M; Teva Pharmaceuticals, West Chester, Pennsylvania., Savola JM; Teva Pharmaceuticals, Basel, Switzerland., Gordon MF; Teva Pharmaceuticals, West Chester, Pennsylvania., Alexander JK; Teva Pharmaceuticals, West Chester, Pennsylvania., Barkay H; Teva Pharmaceuticals, Netanya, Israel., Harary E; Teva Pharmaceuticals, Netanya, Israel.
Publikováno v: JAMA network open [JAMA Netw Open] 2021 Oct 01; Vol. 4 (10), pp. e2129397. Date of Electronic Publication: 2021 Oct 01.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje